1. Home
  2. NRIX

NRIX

Nurix Therapeutics Inc. Common stock

Logo Nurix Therapeutics Inc. Common stock

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.

Founded: 2009 Country:
United States
United States
Employees: N/A City: SAN FRANCISCO
Market Cap: 845.9M IPO Year: 2020
Target Price: $21.86 AVG Volume (30 days): 855.7K
Analyst Decision: Buy Number of Analysts: 7
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.66 EPS Growth: N/A
52 Week Low/High: $4.22 - $18.12 Next Earning Date: 04-10-2024
Revenue: $80,887,000 Revenue Growth: 94.02%
Revenue Growth (this year): -8.39% Revenue Growth (next year): 8.30%

Share on Social Networks: